Novartis division Sandoz recalls one lot of blood pressure drug

Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug.

The drug is made by China’s Zhejiang Huahai Pharmaceutical Co Ltd. Last month, the European Medicines Agency placed the firm under high supervision after a probable carcinogen was found in its blood pressure drug valsartan.

A review was extended to other ‘sartan’ medicines, including candesartan, irbesartan, losartan, olmesartan and valsartan, after very low levels of a carcinogen was found in losartan made by Hetero Labs in India.

Novartis said Sandoz had not received any reports of adverse events related to this lot.

(Reporting by Arunima Banerjee in Bengaluru; Editing by Chris Reese)

  • Related Posts

    After two years, pharma volumes pick up pace

    NEW DELHI: The domestic pharmaceutical retail market is showing its strongest signs yet of a shift from price-led to demand-led growth. Volume growth crossed 3% in June, the first time…

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    The National Pharmaceutical Pricing Authority (NPPA) has allowed an increase in the retail price of anti-rabies immunoglobulin while fixing the retail prices of 39 drug formulations.  According to a gazette…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    After two years, pharma volumes pick up pace

    After two years, pharma volumes pick up pace

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    NPPA fixes prices of 39 drugs, raises anti-rabies immunoglobulin rate

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Tambaram police arrest two persons after seizing 1,100 banned tablets, 5 kg ganja

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Rajasthan Healthcare Crisis: 8 Mothers Die Post-C-Section

    Steroid cream misuse fuels spurt in fungal infections

    Steroid cream misuse fuels spurt in fungal infections

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue